Literature DB >> 22864499

National performance measures within a changing environment: how a federal agency developed and improved the measurement for HIV care and treatment.

Tracy Matthews1, Lori DeLorenzo, Marlene Matosky, Steven Young, Anna Huang, Brian Feit, Faye Malitz, Laura Cheever.   

Abstract

The United States Department of Health and Human Services (HHS) must ensure that access to high quality care is provided through the Ryan White HIV/AIDS Program (RWP). The RWP is committed to improving the quality of care and services to reduce mortality and improve quality of life for people living with HIV. This commitment is evidenced by the comprehensive range of efforts taken by the HHS, Health Resources and Services Administration (HRSA), HIV/AIDS Bureau (HAB) to address the quality of care, treatment and other services across all programs funded by the RWP. To assure high quality care, HRSA/HAB engages in many quality initiatives, with the development of performance measures as a central core of its overall activities. The HRSA/HAB defined a solid foundation for the measures development process, which has been refined over time, facilitating the timely release and use of performance measures by the HIV service provider community.

Entities:  

Mesh:

Year:  2012        PMID: 22864499     DOI: 10.1353/hpu.2012.0128

Source DB:  PubMed          Journal:  J Health Care Poor Underserved        ISSN: 1049-2089


  2 in total

1.  Management of Cytomegalovirus, Epstein-Barr Virus, and HIV Viral Load Quality Control Data Using Unity Real Time.

Authors:  Duane W Newton; Nico Vandepoele; John C Yundt-Pacheco; David Gauthier; Michael A Bachman
Journal:  J Clin Microbiol       Date:  2021-10-20       Impact factor: 5.948

2.  HIV-related outcome disparities between transgender women living with HIV and cisgender people living with HIV served by the Health Resources and Services Administration's Ryan White HIV/AIDS Program: A retrospective study.

Authors:  Pamela W Klein; Demetrios Psihopaidas; Jessica Xavier; Stacy M Cohen
Journal:  PLoS Med       Date:  2020-05-28       Impact factor: 11.069

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.